CXCL12 and Wiskott-Aldrich syndrome: To evaluate whether the normalization of B-cell subset distribution in the BM and PB in treated patients was associated with a qualitative improvement in B-cell function, we tested their in vitro chemotactic response to SDF-1α, which we previously described as defective in patients with WAS.18